3946592
Last Update Posted: 2024-04-04
Recruiting has ended
All Genders accepted | 19 Years-65 Years |
148 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
DWJ211 is a injectable drug for improvement in the appearance of moderate to severe submental fat (SMF)
Eligibility
Relevant conditions:
Submental Fat
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Data sourced from ClinicalTrials.gov